|2.||Neoplasm Metastasis (Metastasis)
|3.||Melanoma (Melanoma, Malignant)
|4.||Breast Neoplasms (Breast Cancer)
|5.||Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
|1.||Rini, Brian I: 118 articles (12/2015 - 04/2002)|
|2.||Escudier, Bernard: 101 articles (12/2015 - 07/2003)|
|3.||Motzer, Robert J: 94 articles (02/2016 - 01/2002)|
|4.||Bukowski, Ronald M: 82 articles (01/2013 - 07/2002)|
|5.||Choueiri, Toni K: 77 articles (01/2016 - 12/2003)|
|6.||Figlin, Robert A: 70 articles (02/2015 - 09/2002)|
|7.||Wood, Christopher G: 68 articles (09/2015 - 08/2003)|
|8.||Leibovich, Bradley C: 63 articles (12/2015 - 04/2003)|
|9.||Jonasch, Eric: 61 articles (01/2016 - 11/2003)|
|10.||Lohse, Christine M: 61 articles (12/2015 - 04/2002)|
|1.||sunitinib (Sutent)FDA Link
04/01/2015 - "We report a case of poor-risk metastatic renal cell carcinoma, with Von Hippel-Lindau loss of function, which achieved and maintained a complete remission after first-line therapy with sunitinib by using a reduced dosage and a modified schedule of treatment. "
04/01/2015 - "Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy."
12/01/2014 - "We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. "
09/01/2011 - "We report a case with a complete pathology-proven remission after sunitinib treatment of a relapsed irresectable clear cell renal carcinoma. "
09/01/2014 - "In a randomized Phase III trial of treatment-naive patients with metastatic renal cell carcinoma (mRCC), patients treated with sunitinib showed a significant improvement in progression-free survival compared with those treated with IFN-α. "
02/01/2000 - "With prolonged follow-up, treatment with high-dose recombinant IL-2 remains extremely effective for a subset of patients with metastatic renal cell carcinoma."
09/01/2011 - "Although the new agents result in a progression-free survival benefit, high-dose IL-2 remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC). "
11/01/2005 - "Interleukin-2 (IL-2) has been shown to produce durable complete remission in patients with renal cell carcinoma (RCC). "
09/01/1999 - "High dose i. v. IL-2 therapy in metastatic renal cell carcinoma has been proven effective . "
01/17/1990 - "A phase II trial of intermittent high-dose recombinant interleukin-2 (rIL-2) was initiated to evaluate the response rate, remission duration, and toxic effects in patients with measurable metastatic renal cell carcinoma. "
|3.||sorafenib (BAY 43-9006)FDA Link
11/01/2011 - "Sorafenib was effective in Japanese patients with advanced renal cell carcinoma in general clinical practice and was tolerated although most patients required dose reduction or interruption of therapy. "
02/01/2013 - "Sorafenib has proven efficacy in metastatic renal cell carcinoma (mRCC). "
08/01/2008 - "Sorafenib is an oral multikinase inhibitor that has been proven effective as a single-agent therapy in renal cell carcinoma, and there is a strong rationale for investigating its use in combination with other agents. "
06/01/2007 - "These findings are consistent with other clinical results from this trial of advanced renal cell carcinoma patients treated with sorafenib, which included significantly greater progression-free survival and low risk for treatment limited toxicities."
01/01/2011 - "High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma."
|4.||Interferon-alpha (Interferon Alfa)FDA Link
05/01/2009 - "Efficacy of adjuvant interferon-alpha therapy following curative resection in renal cell carcinoma: before the molecular targeting therapy era."
08/15/2001 - "Interferon-alpha has proven effective in the treatment of metastatic renal cell carcinoma. "
07/07/2003 - "Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome."
06/01/2010 - "A systematic review was undertaken to determine whether interferon-alfa (IFN-alpha) is an effective treatment for patients with inoperable locally advanced or metastatic renal cell carcinoma (mRCC). "
04/01/2006 - "Interferon-alpha (IFN) is widely used for the treatment of progressive renal cell carcinoma (RCC), but its effective response rate is only about 15%. "
|5.||Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/01/2013 - "Tyrosine kinase inhibitors have dramatically improved the prognosis of metastatic renal cell carcinoma (RCC). "
08/01/2012 - "Tyrosine kinase inhibitors (TKIs) have dramatically improved the outcome of renal cell carcinoma (RCC) patients. "
02/10/2012 - "Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. "
02/10/2012 - "Complete remission with tyrosine kinase inhibitors in renal cell carcinoma."
12/01/2013 - "Although targeted therapies (ie, tyrosine kinase inhibitors and antiangiogenesis agents) are effective as first-line treatment of metastatic renal cell carcinoma (mRCC), moderate-to-severe adverse events have been reported in clinical trials of these agents. "
03/01/1985 - "A case of metastatic renal cell carcinoma in which complete remission was achieved using Interferon therapy is reported. "
03/01/1985 - "[A case of metastatic renal cell carcinoma with complete remission achieved by interferon therapy]."
09/01/2006 - "Immunomodulary therapy based on interferon (IFN)-a has been shown to be effective in a subset of patients with advanced renal cell carcinoma (RCC). "
11/01/1993 - "A clinical study was conducted to evaluate the efficacy of combination therapy with interferon (IFN) alpha and gamma in 16 patients with advanced renal cell carcinoma whom we observed between August 1986 and June 1992. "
02/01/1990 - "Efficacy of interferon to metastatic renal cell carcinoma in this study is limited. "
01/01/2011 - "Temsirolimus appears to be an effective and well-tolerated substance in the treatment of patients with a good performance status, low MSKCC score and stable disease under previous antiangiogenic treatment in advanced renal cell cancer. "
01/01/2011 - "We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. "
05/11/2010 - "Temsirolimus was approved in Europe as first-line treatment of poor-prognosis advanced renal cell carcinoma (advRCC) based on significant clinical benefits. "
10/01/2008 - "Temsirolimus demonstrates a significant improvement in overall survival in patients with advanced renal cell carcinoma and poor-prognostic features, thereby validating the importance of mTOR in the natural history of this disease. "
06/01/2012 - "Temsirolimus is an effective treatment for renal cell carcinoma. "
10/01/2010 - "In oncology, everolimus has been proven effective for the management of treatment-resistant renal cell carcinoma. "
01/01/2012 - "We report an unexpectedly high efficacy of everolimus as a third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. "
11/05/2015 - "This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. "
11/01/2013 - "The aim of the study was to assess the safety and efficacy of everolimus therapy for advanced renal cell carcinoma in Japanese patients receiving real-world care. "
10/01/2013 - "This study evaluates the safety and efficacy of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC). "
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/01/2014 - "VEGF-targeted therapy is currently the first line treatment for patients with metastatic clear cell renal cell carcinoma (ccRCC), but most patients either display primary (intrinsic) resistance or acquire drug resistance. "
11/01/2015 - "In the past decade, targeted therapy with VEGF and mTOR inhibition has significantly improved the outcome of renal cell carcinoma. "
01/01/2015 - "Despite the improvement in progression-free survival and response rates, none of the five anti- VEGF/VEGFR agents used for treatment of metastatic renal cell carcinoma (mRCC) reported a significant increase in patients' survival. "
08/01/2012 - "Vascular endothelial growth factor (VEGF) inhibitors have significantly improved outcomes in patients with advanced renal cell carcinoma (RCC). "
06/01/2007 - "Integrated approaches involving surgery and vascular endothelial growth factor targeted therapies hold much promise for the management of advanced renal cell carcinoma. "
09/01/2013 - "A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN."
09/01/2013 - "Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-α2a (IFN; 9 MIU tiw) in first-line metastatic renal cell carcinoma (mRCC). "
01/01/2008 - "Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma."
02/01/2015 - "Eleven patients with metastatic renal cell carcinoma were enrolled in a multiparametric study of the treatment effects of bevacizumab. "
09/01/2013 - "In this phase II trial, we evaluated the efficacy and safety of 2 escalated doses of bevacizumab in patients with advanced clear cell renal carcinoma. "
07/01/2007 - "Radical nephrectomy is still the best option for treatment of renal cell carcinoma. "
09/22/2001 - "Surgery is the main treatment for localised renal cell carcinoma, but use of radical nephrectomy for metastatic disease is highly controversial. "
10/01/1989 - "On the basis of these data, we believe that radical nephrectomy remains the best treatment for all patients who have renal cell carcinoma and a normal contralateral kidney."
11/01/2011 - "Despite benefits in functional renal outcome and the similar oncological efficacy of partial nephrectomy for renal cell carcinoma, previous studies show marked underuse of partial nephrectomy. "
03/01/2015 - "Laparoscopic radical nephrectomy has proven itself as the "gold standard" treatment of renal cell carcinoma. "
08/01/2007 - "In metastatic renal cell carcinoma (RCC) immunotherapy results in a small but important improvement in overall survival, but a need exists to develop more-effective systemic therapies. "
01/01/2007 - "Hopefully these will very soon contribute to an improvement in renal cell carcinoma specific immunotherapy and its evaluation."
08/01/2008 - "Metastatic renal cell carcinoma (mRCC) has long been treated only by immunotherapy with good results only in a small population of patients. "
12/01/2011 - "Immunotherapy which has been in practice for more than 20 years proves effective for the treatment of metastatic renal cell carcinoma (mRCC). "
06/01/1997 - "Improved understanding of the cellular and molecular basis of renal cell carcinoma recognition opens new avenues of research with the potential to develop better immunotherapies for patients with metastatic disease."
|3.||Drug Therapy (Chemotherapy)
11/01/1987 - "A rare case of metastatic renal cell carcinoma which represented complete remission by chemotherapy and surgical treatment is presented. "
11/01/1987 - "[Complete remission of advanced renal cell carcinoma by chemotherapy and surgical treatment: a case report]."
02/01/1993 - "Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma?"
10/01/1991 - "Neither chemotherapy nor radiation therapy has been shown to be effective against metastatic renal cell carcinoma. "
07/01/1996 - "Promising results of recent clinical trials with a triple drug bio-chemotherapy regimen encouraged its use in patients with renal cell carcinoma. "
12/01/1980 - "Postoperative radiotherapy shows significant improvement in the treatment of hypernephroma. "
02/01/2015 - "Stereotactic radiotherapy is a non-invasive, ablative technique which may be particularly effective in treating metastatic renal cell carcinoma (RCC). "
03/01/1994 - "The efficacy of radiotherapy of renal cell carcinomas is limited by its side effects. "
09/01/2010 - "Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials."
01/01/2006 - "A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma."
|5.||Heterologous Transplantation (Xenotransplantation)
03/01/2008 - "In order to assess the impact of improving linker stability beyond mc containing ADCs, a series of mc and bac-linked 1F6-MMAF conjugates were compared for tolerability, intratumoral drug delivery, and therapeutic efficacy in nude mice with renal cell carcinoma xenografts. "
06/01/2013 - "We tested the efficacy of the CRM1 inhibitors KPT-185 and 251 in several renal cell carcinoma cell lines and in a renal cell carcinoma xenograft model. "
12/15/1997 - "Two human renal cell carcinoma cell lines, Caki-1 and A498, were used in vitro and nude mouse xenograft studies. "
11/15/1996 - "In this study, the relationship between the macroscopic growth pattern of first-generation xenografts of human renal cell carcinomas in nude mice and prognosis was studied. "
07/09/1991 - "A study was made of the relative effects of size and binding strength of various forms of the monoclonal antibody (MAb) G250, reacting with primary and metastatic human renal-cell carcinoma (RCC), on the localization in human RCC xenografts in nude mice. "